Hi-Tech Pharmacal
Executive Summary
Warning letter sent July 23 citing current Good Manufacturing Practices deviations in stability testing at Hi-Tech's Amityville, N.Y. facility which produces neomycin and timolol solutions. Hi-Tech will include new SOP training procedures in a clarified response that is expected Aug 12